CA
NZ
UK
AU
IND
US
Director Paul W. Harvey filed a Form 4 with the SEC on November 9, 2026, disclosing a purchase of 500 shares of Matador Resources Co common stock on November 5, 2026, at a price of $52.72 per share.
SciSparc Ltd. filed a Form 6-K/A on November 9, 2026, amending its November 3, 2026 Form 6-K to correct a typographical error in the Floor Price contained in a Convertible Promissory Note and related Warrant issued to L.I.A. Pure Capital Ltd.
Davion Healthcare Plc filed a Form 6-K on November 9, 2026, disclosing that it entered into a non-exclusive financial advisory agreement with Vienna Capital Partners LLC to support a proposed acquisition financing strategy for 2027.
Heron Therapeutics, Inc. filed a Form 8-K on November 9, 2026, disclosing that on November 8, 2026, it entered into an Asset Purchase Agreement with CorMedix Inc. to sell substantially all of its assets for a combination of cash, stock, royalties, and potential earn-out …
Joseph Wm. Foran, Chairman and CEO of Matador Resources Co, filed a Form 4 with the SEC on November 9, 2026, disclosing an open-market purchase of 5,000 shares of common stock on November 5, 2026, at a weighted average price of $51.36 per share.
Popular, Inc. filed a Current Report on Form 8-K on November 9, 2026, disclosing a $38 million additional provision for credit losses recognized as a subsequent event in its third-quarter 2026 financial statements, stemming from a quick service restaurant borrower that filed for Chapter …
ADC Therapeutics SA (NYSE:ADCT) reported its third-quarter 2026 financial results on November 9, 2026, disclosing net product revenues of $21.0 million and cash and cash equivalents of $189.2 million as of September 30, 2026, alongside details of a strategic financial restructuring completed in October …
The Goodyear Tire & Rubber Company filed an 8-K on November 9, 2026, announcing that board director Roger Wood has been appointed interim chief executive officer, effective immediately, following the departure of Mark Stewart as CEO, president, and board member.
Inovio Pharmaceuticals, Inc. filed a Form 8-K with the SEC on November 9, 2026, disclosing the pricing and terms of a public offering of common stock and pre-funded warrants expected to generate approximately $80.5 million in net proceeds.
Atea Pharmaceuticals, Inc. filed a Current Report on Form 8-K on November 9, 2026, disclosing that it entered into a Loan and Security Agreement with Hercules Capital, Inc. on November 6, 2026, providing for term loans of up to $200.0 million.
Please wait processing your request...